MD431C2 - Procedeu de obţinere a interferonului leucocitar - Google Patents

Procedeu de obţinere a interferonului leucocitar

Info

Publication number
MD431C2
MD431C2 MD94-0340A MD940340A MD431C2 MD 431 C2 MD431 C2 MD 431C2 MD 940340 A MD940340 A MD 940340A MD 431 C2 MD431 C2 MD 431C2
Authority
MD
Moldova
Prior art keywords
pst
pbr
hc1f
interferone
preparation
Prior art date
Application number
MD94-0340A
Other languages
English (en)
Russian (ru)
Inventor
Weissman Charles
Original Assignee
Biogen, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8187070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD431(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen, Inc filed Critical Biogen, Inc
Publication of MD431C2 publication Critical patent/MD431C2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/832—Bacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/832—Bacillus
    • Y10S435/839—Bacillus subtilis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Utilizare: ingineria genetică, obţinerea interferonului leucocitar.Esenţa invenţiei: procedeul include descoperirea şi separarea succesiunilor ADN şi construirea moleculelor recombinante ale ADN, care codifică polipeptidul, având activitate imunologică şi biologică a IFNU-α.Sunt obţinuţi ADN recombinanţi de plasmidă, care conţin ADN cu succesiunile Z-pBR 322 (Pst) HC1F-4c, Z-pBR 322 (Pst) HlF-2h, Z-pBR 322 (Pst) Hc1F-SN-35, Z-pBR 322 (Pst) Hc1F-SN-42, Z-pKT 287 (Pst) HclF-2h-AH6, precum şi succesiunile care se hibridizează cu intercalările expuse.
MD94-0340A 1980-01-08 1994-10-17 Procedeu de obţinere a interferonului leucocitar MD431C2 (ro)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP80300079 1980-01-08

Publications (1)

Publication Number Publication Date
MD431C2 true MD431C2 (ro) 1996-07-31

Family

ID=8187070

Family Applications (1)

Application Number Title Priority Date Filing Date
MD94-0340A MD431C2 (ro) 1980-01-08 1994-10-17 Procedeu de obţinere a interferonului leucocitar

Country Status (7)

Country Link
US (1) US4530901A (ro)
JP (2) JPS56150100A (ro)
IN (1) IN153751B (ro)
MD (1) MD431C2 (ro)
SU (1) SU1764515A3 (ro)
UA (1) UA13380A (ro)
ZA (1) ZA81103B (ro)

Families Citing this family (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835557B1 (en) * 1980-01-08 2004-12-28 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
EP0042246B1 (en) * 1980-06-12 1987-03-18 The Cancer Institute Of Japanese Foundation For Cancer Research Plasmid
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4810645A (en) * 1981-08-14 1989-03-07 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L
IE54592B1 (en) * 1982-03-08 1989-12-06 Genentech Inc Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
US5399684A (en) * 1982-05-20 1995-03-21 Washington Research Foundation DNA sequences expressing mammalian alpha-1-antitrypsin
DE3220116A1 (de) * 1982-05-28 1983-12-01 Dr. Karl Thomae Gmbh, 7950 Biberach Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung
JPS60222500A (ja) * 1983-12-19 1985-11-07 シエリング・コ−ポレ−シヨン 新規ハイブリツドインタ−フエロン
US5248666A (en) * 1984-03-23 1993-09-28 Oncogen Methods for inhibiting neoplastic cell proliferation using platelet factor 4
US4710465A (en) * 1984-04-19 1987-12-01 Yale University Junction-fragment DNA probes and probe clusters
SU1364343A1 (ru) * 1984-07-13 1988-01-07 Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Способ получени человеческого лейкоцитарного интерферона альфа-2
US6291662B1 (en) 1984-12-05 2001-09-18 Amgen Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences
US5871956A (en) * 1984-12-06 1999-02-16 Amgen Inc. Recombinant methods for production of serine inhibitors and DNA sequences useful for same
US5900400A (en) * 1984-12-06 1999-05-04 Amgen Inc. Serine protease inhibitor analogs
US6132990A (en) * 1984-12-06 2000-10-17 Amgen Boulder Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences useful for same
US4874743A (en) * 1985-01-10 1989-10-17 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor-like polypeptides
US4879224A (en) * 1985-01-10 1989-11-07 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor polypeptides
US5081019A (en) * 1985-01-10 1992-01-14 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lipocortin-like polypeptides
US4950646A (en) * 1985-01-10 1990-08-21 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human lipocortin-like polypeptides
JPH088870B2 (ja) 1985-02-05 1996-01-31 サイナ−ゲン バイオロジカルズ，インコ−ポレ−テツド メタロプロテイナ−ゼ阻害剤の配列をもつ組換ベクタ−系及びメタロプロテイナ−ゼ阻害剤製造のための組換ｄｎａ
JPS61185189A (ja) * 1985-02-08 1986-08-18 Green Cross Corp:The 新規インタ−フエロン−α↓１ＤＮＡ配列、組み換えプラスミド及び形質転換体
US4894332A (en) * 1985-03-27 1990-01-16 Biogen, Inc. DNA sequences coding for Mycoplasma hypopneumoniae surface antigens, methods of use to make the corresponding proteins
US4956282A (en) * 1985-07-29 1990-09-11 Calgene, Inc. Mammalian peptide expression in plant cells
US6774283B1 (en) 1985-07-29 2004-08-10 Calgene Llc Molecular farming
US5248603A (en) * 1985-09-03 1993-09-28 Symbicom Aktiebolag Superoxide dismutase
DK402785D0 (da) * 1985-09-03 1985-09-03 Syn Tek Ab Fremgangsmaade til fremstilling af et enzym
US5135868A (en) * 1985-10-25 1992-08-04 Phillips Petroleum Company Cultures of yeast of the genus Pichia altered by site selective genomic modification
US4882279A (en) * 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5089406A (en) * 1987-01-07 1992-02-18 Allied-Signal Inc. Method of producing a gene cassette coding for polypeptides with repeating amino acid sequences
JPH01503513A (ja) * 1987-03-02 1989-11-30 オンコゲン 血小板関連増殖調節剤
JPS6463395A (en) 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
US4961969A (en) * 1987-05-11 1990-10-09 Cetus Corporation Process for recovering microbially produced interferon-β
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5328988A (en) * 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
ATE124087T1 (de) * 1988-02-26 1995-07-15 Biogen Inc Dna-sequenzen, rekombinante dna-moleküle und verfahren zur herstellung von lipocortin iii, iv, v, und vi.
US5605815A (en) * 1988-03-14 1997-02-25 Yale University Nucleic acids encoding and expression of parathyroid hormone-like peptide
WO1989009831A1 (en) * 1988-04-15 1989-10-19 Research Corporation Technologies, Inc. Lak cell cytotoxin
DK455789D0 (da) * 1989-09-15 1989-09-15 Symbicom Ab Polypeptid
JP2772062B2 (ja) * 1989-09-26 1998-07-02 株式会社ニッコー 走行玩具の方向変換装置
US5256568A (en) * 1990-02-12 1993-10-26 Regeneron Phamaceuticals, Inc. Vectors and transformed most cells for recombinant protein production with reduced expression of selectable markers
WO1991015593A1 (en) * 1990-04-02 1991-10-17 Synergen, Inc. Polypeptides useful in diagnosis of and treatment against mycoplasma infections in animals
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
KR100223255B1 (ko) * 1992-02-10 1999-10-15 더글라스 테스타 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로 부터의 제조 방법
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US6869925B1 (en) * 1992-09-09 2005-03-22 Amgen Inc. Inhibition of retrovirus infection
JP2649317B2 (ja) * 1993-10-25 1997-09-03 株式会社キジマ 手袋の製造方法
US6017880A (en) * 1994-03-09 2000-01-25 Amgen Inc. Inhibition of retrovirus infection
CZ296981B6 (cs) * 1994-12-09 2006-08-16 Imperial College Innovations Limited Zpusob pro identifikaci mikroorganizmu, zpusob identifikování genu, mikroorganizmus, vakcína a zpusob její prípravy, zpusob získání mutantního mikroorganizmu, zpusob prípravy farmaceutického prostredku, zpusob identifikace slouceniny a zpusob príprav
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
AU710347B2 (en) * 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
AU7473096A (en) 1995-11-02 1997-05-22 Schering Corporation Continuous low-dose cytokine infusion therapy
US6027721A (en) * 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
GB9712370D0 (en) * 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
DE69815707T2 (de) 1997-11-20 2004-07-01 Vical, Inc., San Diego Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür
HU230432B1 (hu) 1998-05-15 2016-06-28 Merck Sharp & Dohme Corp Ribavirint és alfa-interferont tartalmazó kombinált terápia vírusellenes kezelésben nem részesült, krónikus hepatitis C fertőzött paciensek kezelésében
DE69942925D1 (de) * 1998-09-04 2010-12-16 Emergent Product Dev Uk Ltd Abgeschwächte Salmonella SP12 Mutante als Antigen-Träger.
AR023906A1 (es) 1998-11-12 2002-09-04 Schering Corp MÉTODOS PARA AUMENTAR EL RENDIMIENTO DE UNA COMPOSICIoN INTERFERoN ALFA QUE COMPRENDE LA CONVERSIoN DE ISOFORMA ADJUNTA DEL PIRUVATO DEL INTERFERoN ALFA EN INTERFERoN ALFA.
US6281337B1 (en) 1998-11-12 2001-08-28 Schering Corporation Methods for conversion of protein isoforms
JP2000319195A (ja) 1999-04-08 2000-11-21 Schering Plough Corp 黒色腫治療
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6923966B2 (en) * 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
GB0008419D0 (en) * 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
WO2001079444A2 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc Albumin fusion proteins
GB0008966D0 (en) * 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
PT1377251E (pt) * 2001-02-20 2008-08-05 Ortho Mcneil Janssen Pharm Método de terapia celular para o tratamento de tumores
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
SK14272003A3 (sk) 2001-04-24 2004-04-06 Merck Patent Gmbh Kombinovaná terapia pri použití antiangiogénových činidiel a TNFalfa
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
GB0304993D0 (en) * 2003-03-05 2003-04-09 Univ Nottingham Trent Novel screening method
CN103495153A (zh) 2003-10-23 2014-01-08 奇尼塔二有限责任公司 检测与抗病毒感染性有关的基因oas1中的突变的方法
US8420087B2 (en) * 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
GB2426521A (en) 2004-02-02 2006-11-29 Ambrx Inc Modified human four helical bundle polypeptides and their uses
GB0420091D0 (en) * 2004-09-10 2004-10-13 Univ Nottingham Trent Medical implant materials
US20060193849A1 (en) * 2005-02-25 2006-08-31 Antisoma Plc Biological materials and uses thereof
GB0514661D0 (en) * 2005-07-16 2005-08-24 Medical Res Council Methods
DK1760088T3 (da) 2005-09-05 2008-06-09 Immatics Biotechnologies Gmbh Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekyler
EP1760089B1 (en) 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
JP5055284B2 (ja) 2005-09-20 2012-10-24 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー インシュリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
GB0607354D0 (en) * 2006-04-12 2006-05-24 Bioinvent Int Ab Agent, Composition And Method
GB0607798D0 (en) * 2006-04-20 2006-05-31 Alligator Bioscience Ab Novel polypeptides and use thereof
EP2021791A2 (en) * 2006-05-31 2009-02-11 Unilever N.V. Method of screening for compounds that alter skin and/or hair pigmentation
US8334365B2 (en) * 2006-06-07 2012-12-18 Human Genome Sciences, Inc. Albumin fusion proteins
NZ582822A (en) 2007-07-27 2012-06-29 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
CN103911358B (zh) 2007-07-27 2017-03-01 伊玛提克斯生物技术有限公司 神经元和脑肿瘤的新型免疫疗法
JPWO2009028573A1 (ja) 2007-08-27 2010-12-09 国立大学法人名古屋大学 血液凝固障害におけるリバビリンの利用
EP2612868B1 (en) 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
US20100249373A1 (en) * 2007-11-27 2010-09-30 Richard Martin Ogborne Screening methods
HUE028261T2 (en) 2008-03-27 2016-12-28 Immatics Biotechnologies Gmbh New immunotherapy for neuronal and brain tumors
SI2119726T2 (en) 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
EP2326344A4 (en) 2008-06-16 2013-08-07 Prokarium Ltd VACCINES WITH SALMONELLA VECTOR AGAINST CHLAMYDIA AND METHOD OF ADMINISTRATION
DK2172211T3 (en) 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
AU2009298182B2 (en) * 2008-10-03 2013-07-11 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Treatment of hepatitis C infection with metalloporphyrins
ES2342529B1 (es) 2008-10-07 2011-05-11 Proyecto De Biomedicina Cima, S.L. Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
JP2012513200A (ja) 2008-12-23 2012-06-14 シェーリング コーポレイション 組換え製造インターフェロンの精製
GB0905790D0 (en) 2009-04-03 2009-05-20 Alligator Bioscience Ab Novel polypeptides and use thereof
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
US8623348B2 (en) 2009-03-27 2014-01-07 Jw Pharmaceutical Corporation Interferon-α (IFN-α) fused proteins comprising IFN-α and a cytoplasmic transduction peptide (CTP)
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
WO2011014726A1 (en) 2009-07-31 2011-02-03 Osi Pharmaceuticals, Inc. Mtor inhibitor and angiogenesis inhibitor combination therapy
AU2010297557C1 (en) 2009-09-25 2017-04-06 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
JP5794532B2 (ja) * 2009-10-16 2015-10-14 学校法人立命館 インターフェロン−αモジュレーター
US8822496B2 (en) 2009-10-30 2014-09-02 Boehringer Ingelheim International Gmbh Dosage regimens for HCV combination therapy
EP2513146B1 (en) 2009-12-18 2017-05-03 Kancera AB Antibodies against ror1 capable of inducing cell death of cll
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
JP2013527748A (ja) 2010-03-03 2013-07-04 オーエスアイ・ファーマシューティカルズ，エルエルシー インスリン様増殖因子１受容体キナーゼ阻害剤に対する抗癌反応の予測に役立つ生物学的マーカー
GB201019331D0 (en) 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
JP5868948B2 (ja) 2010-04-19 2016-02-24 オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． リジン特異的脱メチル化酵素１阻害薬およびその使用
CA2803093A1 (en) 2010-06-24 2011-12-29 Panmed Ltd. Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
BR112013002164B1 (pt) 2010-07-29 2021-11-09 Oryzon Genomics S.A. Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
EP2712316A1 (en) 2011-02-08 2014-04-02 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
EP3981395A1 (en) 2011-02-08 2022-04-13 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
CN107417549A (zh) 2011-10-20 2017-12-01 奥莱松基因组股份有限公司 作为lsd1抑制剂的（杂）芳基环丙基胺化合物
AU2012332827A1 (en) 2011-10-31 2014-05-15 Gilead Pharmasset Llc Methods and compositions for treating hepatitis C virus
BR112014012739A8 (pt) 2011-11-29 2017-06-20 Gilead Pharmasset Llc composições e métodos para o tratamento do vírus da hepatite c
JP2015509980A (ja) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
GB201219678D0 (en) 2012-11-01 2012-12-12 Benf Ab Ketone body inhibitors and uses thereof
EP2961766B1 (en) 2013-03-01 2019-04-10 Boehringer Ingelheim Vetmedica, Inc. Quantification of vaccine compositions
WO2014197400A1 (en) 2013-06-04 2014-12-11 Gilead Pharmasset Llc Preventing and treating recurrence of hcv infection after liver transplant
TWI775117B (zh) 2013-08-05 2022-08-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二）
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2015149721A1 (en) 2014-04-04 2015-10-08 Crown Bioscience, Inc.(Taicang) Methods for determining responsiveness to mek/erk inhibitors
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
PL3545965T3 (pl) 2014-12-23 2021-12-27 Immatics Biotechnologies Gmbh Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem raka komórek wątroby (hcc) i innych rodzajów raka
CN109265517B (zh) 2015-03-27 2024-05-10 伊玛提克斯生物技术有限公司 用于各种肿瘤免疫治疗的肽和肽组合物
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PE20230321A1 (es) 2015-07-01 2023-02-22 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
MX2017017148A (es) 2015-07-06 2018-02-23 Immatics Biotechnologies Gmbh Peptidos novedosos y combinacion de peptidos para usarse en la inmunoterapia contra cancer esofagico y otros canceres.
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
CA3006743A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
IL302705A (en) 2016-03-01 2023-07-01 Immatics Biotechnologies Gmbh Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
ES2968802T3 (es) 2016-03-16 2024-05-14 Immatics Biotechnologies Gmbh Células T transfectadas y receptores de células T para su uso en inmunoterapia contra el cáncer
LT3430037T (lt) 2016-03-16 2022-12-12 Immatics Biotechnologies Gmbh Transfekuotos t ląstelės ir t ląstelių receptoriai, skirti naudoti vėžio gydymui taikant imunoterapiją
CN109071605A (zh) 2016-04-06 2018-12-21 伊玛提克斯生物技术有限公司 用于aml和其他癌症免疫治疗的新型肽和肽组合物
TWI796299B (zh) 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
MA47367B1 (fr) 2017-01-27 2023-06-28 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
WO2018189148A1 (en) 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
EA201992416A1 (ru) 2017-04-10 2020-02-25 Имматикс Байотекнолоджиз Гмбх Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
CR20210160A (es) 2017-04-10 2021-04-26 Immatics Biotechnologies Gmbh Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508)
US10800823B2 (en) 2017-07-07 2020-10-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
EP3648790A1 (en) 2017-07-07 2020-05-13 Immatics Biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
TW202028224A (zh) 2018-09-17 2020-08-01 德商英麥提克生物技術股份有限公司 B*44限制肽在抗癌免疫治療的用途和相關方法
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202229312A (zh) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
WO2025040598A2 (en) 2023-08-18 2025-02-27 Immatics Biotechnologies Gmbh Peptides displayed by mhc for use in immunotherapy against different types of cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3699222A (en) * 1958-03-11 1972-10-17 Nat Res Dev Production of viral interfering substances
GB1412591A (en) * 1971-11-30 1975-11-05 Beecham Group Ltd Antiviral ds rna and compositions thereof
US4184917A (en) * 1974-04-01 1980-01-22 Sandoz Ltd. Process for producing a structurally modified interferon
GB1521032A (en) * 1974-08-08 1978-08-09 Ici Ltd Biological treatment
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4190495A (en) * 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
DE2724918A1 (de) * 1977-06-02 1978-12-14 Thomae Gmbh Dr K Gewinnung und reinigung von humaninterferon
ZA782933B (en) * 1977-09-23 1979-05-30 Univ California Purification of nucleotide sequences suitable for expression in bacteria
FR2422956A1 (fr) * 1978-04-13 1979-11-09 Pasteur Institut Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede
JPS5519239A (en) * 1978-07-28 1980-02-09 Green Cross Corp:The Interferon-producing attractant
FI792481A7 (fi) * 1978-08-11 1981-01-01 The Regents Of The Univ Of Enkaroyyttisen proteiinin synteesi mikro-organismia käyttäen.
GB2033905B (en) * 1978-08-21 1982-10-13 Upjohn Co Bacterial preparation of proteins
JPS5561798A (en) * 1978-10-30 1980-05-09 Noda Sangyo Kagaku Kenkyusho Preparation of novel recombination dna
FR2440957A1 (fr) * 1978-11-13 1980-06-06 Pasteur Institut Vecteurs appropries a l'insertion dans leurs genomes de fragments d'adn etrangers, selon l'une quelconque des phases de traduction possibles, et moyens pour leur fabrication
US4241174A (en) * 1978-11-24 1980-12-23 Hoffmann-La Roche Inc. Interferon assay
IN150740B (ro) * 1978-11-24 1982-12-04 Hoffmann La Roche
FR2444713A1 (fr) * 1978-12-18 1980-07-18 Pasteur Institut Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant
FI77877C (fi) * 1979-04-20 1989-05-10 Technobiotic Ltd Foerfarande foer framstaellning och rening av human le-formig interferonprotein.
ZA802992B (en) * 1979-06-01 1981-10-28 Univ California Human pre-growth hormone
US4262090A (en) * 1979-06-04 1981-04-14 Cetus Corporation Interferon production

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Proc. Natl. Acad. Sci., USA 76, p. 640-644, 1979. *

Also Published As

Publication number Publication date
UA13380A (uk) 1997-02-28
IN153751B (ro) 1984-08-18
JPH0321150B2 (ro) 1991-03-22
US4530901A (en) 1985-07-23
SU1764515A3 (ru) 1992-09-23
JPH0321151B2 (ro) 1991-03-22
ZA81103B (en) 1982-01-27
JPS56150100A (en) 1981-11-20
JPS62122590A (ja) 1987-06-03

Similar Documents

Publication Publication Date Title
MD431C2 (ro) Procedeu de obţinere a interferonului leucocitar
MD430C2 (ro) Procedeu de obţinere a interferonelor leucocitare umane
DE3689195D1 (de) Verfahren zur Herstellung von Aloe-Erzeugnissen, Erzeugnisse und Zusammensetzungen dazu.
ES2009286A6 (es) Metodos para preparar acido nucleico bicatenario con una secuencia objetivo, detectar dicha secuencia y multiplicar un segmento de acido nucleico objetivo, y estuche de deteccion correspondiente.
YU55683A (en) Process for expressiation, altering and excreting heterologic proteine by using yeast
DE3872046D1 (de) Gastrennverfahren.
DE3689196D1 (de) Verfahren zur Herstellung von Amiden unter Verwendung von Mikroorganismen.
GR3005297T3 (ro)
DE3586697D1 (en) Aktive thymopentin-analoga.
DE3585092D1 (de) Schmelzverarbeitbare copolymere von tetrafluoraethylen und perfluorolefinen und verfahren zu ihrer herstellung.
DK54184D0 (da) Dna-sekvenser,rekombinations-dna-molekyler samt fremgangsmaader til fremstilling af human(interleukin)to-lignende polipeptider
AU5720498A (en) Chemical synthesis of nucleosides analogs and their incorporation into polynucleotides
IT1210142B (it) Nuovo gene beta-urogastrone, corrispondenti plasmidi ricombinanti, corrispondenti trasformanti e metodo per lapreparazione di questi e del beta-urogastrone.
MY101184A (en) Method for the separation of oil-in water emulsions.
EP0255390A3 (en) Rhodococcus bacterium for the production of aryl acylamidase
DE3677401D1 (de) Verfahren zur herstellung von perylen-3,4,9,10-tetracarbonsaeurearylimiden.
DE3577372D1 (de) Verfahren zur herstellung von sonnenzellen aus amorphem silizium und das dadurch erzeugte produkt.
AU4671685A (en) Separation process with recovery of proteins & fats from substances of animal origin, organic substances or refluent from working organic substances & plant to carry out the
DE2962521D1 (en) Process for the purification of long-chain acyl-coenzyme-a synthetase and the enzyme, acyl-coa synthetase, purified thereby
IT8567141A1 (it) Procedimento per le coltura di cellule, mediante dispersione di gas.
IT1216721B (it) Procedimento per la produzione di bricchette di combustibile senza fumo trattate.
HUT46077A (en) Process for the microbiological production of 9alpha-hydroxy-4-androsten-3,17-dione
ES8602123A1 (es) Un metodo para clonar un gen que codifica la cobre-meta-lotioneina de levadura
ZA824376B (en) Process for extracting, concentrating and purifying natural aromas of plant origin and products obtained by this process
IT8622286A0 (it) Procedimento per la raffinazione del carbone mediante agglomerazione selettiva.